Do analysts rate APLM or SYBX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, APLM or SYBX?

Apollomics has higher revenue and earnings than Synlogic. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 7.25 -$10.94M N/A N/A Synlogic $8K 1,867.97 -$23.36M -$0.06 N/A

Is APLM or SYBX more profitable?

Apollomics' return on equity of 0.00% beat Synlogic's return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Synlogic N/A -26.47% -18.00%

Do analysts prefer XLO or SYBX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor XLO or SYBX?

In the previous week, Xilio Therapeutics had 2 more articles in the media than Synlogic. MarketBeat recorded 4 mentions for Xilio Therapeutics and 2 mentions for Synlogic. Xilio Therapeutics' average media sentiment score of 1.25 beat Synlogic's score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xilio Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Synlogic 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SYBX or IMA?

ImageneBio has a consensus price target of $29.00, indicating a potential upside of 493.05%. Given ImageneBio's stronger consensus rating and higher possible upside, analysts plainly believe ImageneBio is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ImageneBio 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.20

Is SYBX or IMA more profitable?

Synlogic's return on equity of -26.47% beat ImageneBio's return on equity. Company Net Margins Return on Equity Return on Assets Synlogic N/A -26.47% -18.00% ImageneBio N/A -38.99% -34.84%

Do analysts recommend INKT or SYBX?

MiNK Therapeutics currently has a consensus target price of $35.00, indicating a potential upside of 211.67%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe MiNK Therapeutics is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is INKT or SYBX more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Synlogic's return on equity. Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -92.37% Synlogic N/A -26.47% -18.00%

Do analysts recommend SYBX or IMMP?

Prima BioMed has a consensus target price of $5.50, suggesting a potential upside of 1,406.44%. Given Prima BioMed's stronger consensus rating and higher probable upside, analysts clearly believe Prima BioMed is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Prima BioMed 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, SYBX or IMMP?

Synlogic has higher earnings, but lower revenue than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synlogic $8K 1,867.97 -$23.36M -$0.06 N/A Prima BioMed $6.69M 8.04 -$39.78M N/A N/A

Is SYBX or IMMP more profitable?

Prima BioMed's return on equity of 0.00% beat Synlogic's return on equity. Company Net Margins Return on Equity Return on Assets Synlogic N/A -26.47% -18.00% Prima BioMed N/A N/A N/A

Does the media refer more to SYBX or IMMP?

In the previous week, Synlogic had 1 more articles in the media than Prima BioMed. MarketBeat recorded 2 mentions for Synlogic and 1 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 0.98 beat Synlogic's score of 0.00 indicating that Prima BioMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synlogic 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Synlogic (SYBX) Competitors

$1.22 +0.01 (+0.62%)

As of 09/3/2026 01:39 PM Eastern

Compare

SYBX vs. APLM, XLO, IMA, INKT, and IMMP

Should you buy Synlogic stock or one of its competitors? Synlogic's main competitors and comparable companies include Apollomics (APLM), Xilio Therapeutics (XLO), ImageneBio (IMA), MiNK Therapeutics (INKT), and Prima BioMed (IMMP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Synlogic compare to Apollomics?

Apollomics (NASDAQ:APLM) and Synlogic (NASDAQ:SYBX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Apollomics' return on equity of 0.00% beat Synlogic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Synlogic	N/A	-26.47%	-18.00%

Apollomics has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market. Comparatively, Synlogic has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market.

In the previous week, Synlogic had 2 more articles in the media than Apollomics. MarketBeat recorded 2 mentions for Synlogic and 0 mentions for Apollomics. Apollomics' average media sentiment score of 0.00 equaled Synlogic'saverage media sentiment score.

Company	Overall Sentiment
Apollomics	Neutral
Synlogic	Neutral

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 2.6% of Synlogic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Apollomics has higher revenue and earnings than Synlogic.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	7.25	-$10.94M	N/A	N/A
Synlogic	$8K	1,867.97	-$23.36M	-$0.06	N/A

Summary

Apollomics beats Synlogic on 5 of the 9 factors compared between the two stocks.

How does Synlogic compare to Xilio Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Synlogic (NASDAQ:SYBX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by insiders. Comparatively, 2.6% of Synlogic shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Xilio Therapeutics had 2 more articles in the media than Synlogic. MarketBeat recorded 4 mentions for Xilio Therapeutics and 2 mentions for Synlogic. Xilio Therapeutics' average media sentiment score of 1.25 beat Synlogic's score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xilio Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Synlogic	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Synlogic has lower revenue, but higher earnings than Xilio Therapeutics. Synlogic is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.36	-$35.04M	-$1.64	N/A
Synlogic	$8K	1,867.97	-$23.36M	-$0.06	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Synlogic has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -34.06%. Synlogic's return on equity of -26.47% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-34.06%	-71.99%	-20.43%
Synlogic	N/A	-26.47%	-18.00%

Xilio Therapeutics has a beta of -0.14, meaning that its share price is 114% less volatile than the broader market. Comparatively, Synlogic has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

Summary

Synlogic beats Xilio Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Synlogic compare to ImageneBio?

Synlogic (NASDAQ:SYBX) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

ImageneBio has a consensus price target of $29.00, indicating a potential upside of 493.05%. Given ImageneBio's stronger consensus rating and higher possible upside, analysts plainly believe ImageneBio is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20

In the previous week, Synlogic had 2 more articles in the media than ImageneBio. MarketBeat recorded 2 mentions for Synlogic and 0 mentions for ImageneBio. Synlogic's average media sentiment score of 0.00 equaled ImageneBio'saverage media sentiment score.

Company	Overall Sentiment
Synlogic	Neutral
ImageneBio	Neutral

Synlogic's return on equity of -26.47% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
ImageneBio	N/A	-38.99%	-34.84%

63.4% of Synlogic shares are held by institutional investors. Comparatively, 75.0% of ImageneBio shares are held by institutional investors. 2.6% of Synlogic shares are held by company insiders. Comparatively, 2.2% of ImageneBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Synlogic has higher earnings, but lower revenue than ImageneBio. Synlogic is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8K	1,867.97	-$23.36M	-$0.06	N/A
ImageneBio	$800K	69.38	-$45.35M	-$4.58	N/A

Synlogic has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market. Comparatively, ImageneBio has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

Summary

ImageneBio beats Synlogic on 8 of the 15 factors compared between the two stocks.

How does Synlogic compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Synlogic (NASDAQ:SYBX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

MiNK Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, Synlogic has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market.

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Synlogic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Synlogic had 2 more articles in the media than MiNK Therapeutics. MarketBeat recorded 2 mentions for Synlogic and 0 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 0.00 equaled Synlogic'saverage media sentiment score.

Company	Overall Sentiment
MiNK Therapeutics	Neutral
Synlogic	Neutral

MiNK Therapeutics' return on equity of 0.00% beat Synlogic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-92.37%
Synlogic	N/A	-26.47%	-18.00%

MiNK Therapeutics currently has a consensus target price of $35.00, indicating a potential upside of 211.67%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe MiNK Therapeutics is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

MiNK Therapeutics has higher earnings, but lower revenue than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A
Synlogic	$8K	1,867.97	-$23.36M	-$0.06	N/A

Summary

MiNK Therapeutics beats Synlogic on 8 of the 13 factors compared between the two stocks.

How does Synlogic compare to Prima BioMed?

Synlogic (NASDAQ:SYBX) and Prima BioMed (NASDAQ:IMMP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

Prima BioMed's return on equity of 0.00% beat Synlogic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
Prima BioMed	N/A	N/A	N/A

Synlogic has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market.

Prima BioMed has a consensus target price of $5.50, suggesting a potential upside of 1,406.44%. Given Prima BioMed's stronger consensus rating and higher probable upside, analysts clearly believe Prima BioMed is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

63.4% of Synlogic shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 2.6% of Synlogic shares are held by insiders. Comparatively, 3.1% of Prima BioMed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Synlogic has higher earnings, but lower revenue than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8K	1,867.97	-$23.36M	-$0.06	N/A
Prima BioMed	$6.69M	8.04	-$39.78M	N/A	N/A

In the previous week, Synlogic had 1 more articles in the media than Prima BioMed. MarketBeat recorded 2 mentions for Synlogic and 1 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 0.98 beat Synlogic's score of 0.00 indicating that Prima BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synlogic	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prima BioMed	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Prima BioMed beats Synlogic on 9 of the 13 factors compared between the two stocks.

Get Synlogic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SYBX vs. The Competition

Export

Metric	Synlogic	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.94M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-4.69	12.66	273.29	25.25
Price / Sales	1,867.97	1,342.79	623.67	97.64
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	1.12	16.39	12.92	6.14
Net Income	-$23.36M	-$22.72M	$3.47B	$349.01M
7 Day Performance	N/A	0.36%	0.60%	-0.27%
1 Month Performance	3.39%	8.53%	5.72%	0.68%
1 Year Performance	-16.44%	52.66%	25.33%	14.84%

Synlogic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SYBX Synlogic	0.0738 of 5 stars	$1.22 +0.6%	N/A	-18.1%	$14.94M	$8K	N/A	80	News Coverage
APLM Apollomics	1.5906 of 5 stars	$26.95 +0.0%	N/A	+569.3%	$59.16M	$8.50M	N/A	45	Analyst Downgrade
XLO Xilio Therapeutics	0.5462 of 5 stars	$8.84 -0.5%	N/A	-11.0%	$58.43M	$43.77M	N/A	70	Positive News Analyst Upgrade
IMA ImageneBio	2.2613 of 5 stars	$4.96 -1.2%	$29.00 +484.7%	-64.4%	$56.98M	N/A	N/A	70
INKT MiNK Therapeutics	2.1711 of 5 stars	$11.33 +3.5%	$35.00 +208.9%	-20.2%	$55.88M	N/A	N/A	30	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SYBX) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Synlogic (SYBX) Competitors

SYBX vs. APLM, XLO, IMA, INKT, and IMMP

How does Synlogic compare to Apollomics?

Summary

How does Synlogic compare to Xilio Therapeutics?

Summary

How does Synlogic compare to ImageneBio?

Summary

How does Synlogic compare to MiNK Therapeutics?

Summary

How does Synlogic compare to Prima BioMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYBX vs. The Competition

Synlogic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Synlogic (SYBX) Competitors

SYBX vs. APLM, XLO, IMA, INKT, and IMMP

How does Synlogic compare to Apollomics?

Do analysts rate APLM or SYBX?

Is APLM or SYBX more profitable?

Which has more volatility & risk, APLM or SYBX?

Does the media refer more to APLM or SYBX?

Do insiders and institutionals believe in APLM or SYBX?

Which has preferable valuation and earnings, APLM or SYBX?

Summary

How does Synlogic compare to Xilio Therapeutics?

Do institutionals & insiders have more ownership in XLO or SYBX?

Does the media favor XLO or SYBX?

Which has preferable earnings & valuation, XLO or SYBX?

Do analysts prefer XLO or SYBX?

Is XLO or SYBX more profitable?

Which has more risk & volatility, XLO or SYBX?

Summary

How does Synlogic compare to ImageneBio?

Do analysts recommend SYBX or IMA?

Does the media refer more to SYBX or IMA?

Is SYBX or IMA more profitable?

Do institutionals and insiders have more ownership in SYBX or IMA?

Which has better earnings & valuation, SYBX or IMA?

Which has more volatility and risk, SYBX or IMA?

Summary

How does Synlogic compare to MiNK Therapeutics?

Which has more volatility & risk, INKT or SYBX?

Do institutionals & insiders believe in INKT or SYBX?

Does the media prefer INKT or SYBX?

Is INKT or SYBX more profitable?

Do analysts recommend INKT or SYBX?

Which has better earnings & valuation, INKT or SYBX?

Summary

How does Synlogic compare to Prima BioMed?

Is SYBX or IMMP more profitable?

Which has more risk and volatility, SYBX or IMMP?

Do analysts recommend SYBX or IMMP?

Do institutionals and insiders hold more shares of SYBX or IMMP?

Which has stronger valuation & earnings, SYBX or IMMP?

Does the media refer more to SYBX or IMMP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYBX vs. The Competition

Synlogic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools